COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 01, 2022 |
May 31, 2023 |
Feb. 28, 2022 |
Jan. 31, 2022 |
Apr. 30, 2017 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
|
| Loss Contingencies [Line Items] | |||||||||||
| Termination agreement description | The employment agreements as amended for the Company’s Executive Chairman and CEO each contain termination provisions whereby if they are terminated without cause or following a material change, as defined therein, they will receive salary through the date of termination plus an additional 24 months, bonus that would be earned during the full year when the termination became effective (or a lump sum of 50% of the full target bonus), all stock options shall vest and healthcare benefits will continue for 24 months. The Company’s General Counsel’s employment agreement, as amended, contains an 18-month severance payment in the instance of a termination without cause or following a material change, as defined therein. In June 2023, the Company’s General Counsel was provided the additional title of Executive Vice President – Corporate Development. | ||||||||||
| Employment agreements description | Pursuant to amendments dated November 14, 2022 to the three employment agreements of the Company’s Executive Chairman, CEO and EVP/General Counsel, as well as an amendment to the employment agreement for the Company’s VP Operations (the “2022 Amendments”), each of these four employees have agreed to accept reduced salaries until the Company is successful in raising additional funds. Specifically, when the Company raises at least $7.5 million in a single offering, each employee’s salary will be increased to the full contracted rate; and prior to that time, the reduced salaries will be gradually increased as the Company raises $2 million and then $5 million. During this time, the difference between the reduced salaries and the full contracted salaries will not accrue as liabilities for the Company. | ||||||||||
| Accrued salary amount | $ 79,166 | $ 79,166 | $ 79,166 | ||||||||
| Estimated fair value | $ 314,246 | ||||||||||
| Stock issued during period, value forfeitures | 5,000,000 | ||||||||||
| Individual compensation expense | 30,000 | ||||||||||
| Professional fees | 449,365 | $ 218,006 | $ 908,499 | $ 857,411 | |||||||
| Employee agreement related description | These shares vest 50% upon a Nasdaq listing of the Company’s stock if completed within three years, and 50% in eight quarterly installments upon the sooner of the Nasdaq listing or 12 months from issuance. All shares will vest upon the sale, merger or other “exit” event of the Company. | ||||||||||
| Issuance of common stock for cash, shares | 962,922 | 34,219 | |||||||||
| Research and development expenses | 448,256 | $ 204,216 | $ 654,795 | $ 459,053 | |||||||
| Chairman and CEO [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Description of nature and effects | The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s EVP/General Counsel and for its VP Operations each contain a similar transaction bonus equal to 1.0% of consideration received by the Company, pursuant to a Board consent authorized and approved as of July 26, 2023 (see Note 9 – Subsequent Events). | ||||||||||
| Adriann Sax [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Individual compensation expense | $ 30,000 | ||||||||||
| Accrued compensation | $ 72,339 | 43,542 | |||||||||
| Adriann Sax [Member] | Restricted Stock [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Restricted stock issued as bonuses | 10,455 | ||||||||||
| Audit Committee [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Professional fees | $ 7,500 | 7,500 | |||||||||
| Nominating and Governace Commmittee [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Professional fees | 3,500 | $ 10,000 | |||||||||
| Charles J. Link [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Individual compensation expense | 30,000 | ||||||||||
| Accrued compensation | 85,283 | $ 51,333 | |||||||||
| Charles J. Link [Member] | Restricted Stock [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Restricted stock issued as bonuses | 10,455 | ||||||||||
| Compensation Committee Chair [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Professional fees | $ 15,000 | ||||||||||
| Settlement Agreement [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Accrued salaries | $ 758,748 | 758,748 | |||||||||
| Estimated fair value | 606,998 | ||||||||||
| Cash payments | 151,750 | ||||||||||
| Unpaid salaries | $ 79,166 | ||||||||||
| Shares issued | 168,611 | ||||||||||
| Converted price per share | $ 3.55 | $ 3.55 | |||||||||
| License Agreement [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Research and development expenses | $ 0 | $ 95,988 | |||||||||
| Accounts payable and accrued expenses | $ 48,978 | $ 48,978 | |||||||||
| License Agreement [Member] | IGL Pharma Inc [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Agreement term | 20 years | ||||||||||
| License Agreement [Member] | QSAM Therapeutics Inc [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Other expenses | $ 56,854 | ||||||||||
| Royalty percentage | 4.50% | ||||||||||
| Sublicense percentage | 5.00% | ||||||||||
| Consulting fee | $ 8,500 | $ 8,500 | |||||||||
| License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Other expenses | $ 2,000,000 | ||||||||||
| Issuance of common stock for cash, shares | 12,500 | ||||||||||
| License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member] | |||||||||||
| Loss Contingencies [Line Items] | |||||||||||
| Other expenses | $ 410,000 | ||||||||||